Clinitech Lab

Why is Clinitech Laboratory Ltd falling/rising?

As of 10-Jun, Clinitech Laboratory Ltd's stock price is rising to 38.00, up 0.53% today and outperforming the sector. However, it remains below its moving averages, indicating a potential bearish trend despite increased investor interest.

As of 10-Jun, Clinitech Laboratory Ltd's stock price is rising, currently at 38.00, with a change of 0.2 (0.53%) upward. This increase is notable as the stock has outperformed the sector by 1.02% today. Additionally, the stock has shown a positive trend over the past week, gaining 0.53%, while the benchmark Sensex has declined by 0.49%. <BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume by 25% against the 5-day average, indicating growing interest in the stock. However, it is important to note that Clinitech Laboratory Ltd is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. <BR><BR>Despite these mixed signals, the current upward movement in the stock price can be attributed to the recent outperformance against the sector and increased investor participation.

Which are the latest news on Clinitech Lab?

How has been the historical performance of Clinitech Lab?

Clinitech Lab's historical performance shows increasing net sales and total assets, but declining profitability metrics such as operating profit and net income over the past three years. Despite challenges in cash flow management, the company reported a net cash inflow of 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Clinitech Lab shows a mixed trend in financial metrics over the past three years.<BR><BR>Breakdown:<BR>Clinitech Lab's net sales increased from 6.35 Cr in Mar'23 to 6.40 Cr in Mar'24, and further to 8.23 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, reaching 8.23 Cr in Mar'25. However, total expenditure also rose significantly from 4.99 Cr in Mar'23 to 7.40 Cr in Mar'25, leading to a decline in operating profit (PBDIT) from 1.36 Cr in Mar'23 to 1.06 Cr in Mar'25. Profit before tax showed a decrease from 0.86 Cr in Mar'23 to 0.55 Cr in Mar'25, while profit after tax also fell from 0.61 Cr in Mar'23 to 0.39 Cr in Mar'25. Despite these declines, earnings per share (EPS) decreased from 4.07 in Mar'23 to 1.71 in Mar'25. On the balance sheet, total assets grew from 5.88 Cr in Mar'23 to 10.55 Cr in Mar'25, with total liabilities increasing from 5.88 Cr to 10.55 Cr in the same period. The company reported a net cash inflow of 2.00 Cr in Mar'25, contrasting with previous years where cash flow from operating activities was negative. Overall, Clinitech Lab's financial performance reflects growth in sales and assets but challenges in profitability and cash flow management.

When is the next results date for Clinitech Lab?

The next results date for Clinitech Lab is 12 November 2025.

The next results date for Clinitech Lab is scheduled for 12 November 2025.

Is Clinitech Lab overvalued or undervalued?

As of August 28, 2025, Clinitech Lab is considered undervalued with a PE ratio of 11.41 and a low PEG ratio of 0.00, indicating a positive shift in its valuation grade to attractive, despite a year-to-date return of -36.6%, while outperforming the Sensex over the past month.

As of 28 August 2025, Clinitech Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.41, an EV to EBITDA ratio of 11.57, and a ROE of 10.99%. These metrics suggest that Clinitech Lab offers a compelling investment opportunity compared to its peers.<BR><BR>In the peer comparison, Clinitech Lab's PE ratio of 11.41 stands in stark contrast to Max Healthcare's exorbitant 93.61 and Apollo Hospitals' 70.56, both of which are categorized as very expensive. Additionally, Clinitech's PEG ratio is notably low at 0.00, further supporting the undervaluation narrative. While the stock has faced challenges with a year-to-date return of -36.6%, it has outperformed the Sensex over the past month, which saw a decline of 1.00%. This performance may indicate a potential recovery and growth trajectory for Clinitech Lab.

How big is Clinitech Lab?

As of 24th July, Clinitech Laboratory Ltd has a market capitalization of 7.00 Cr, classifying it as a Micro Cap company. Financial data for the latest four quarters is unavailable, but as of March 2024, Shareholder's Funds are 3.55 Cr and Total Assets are 5.44 Cr.

As of 24th July, Clinitech Laboratory Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest four quarters, so I cannot provide information on Net Sales or Net Profit.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 3.55 Cr and Total Assets valued at 5.44 Cr.

What does Clinitech Lab do?

Clinitech Laboratory Ltd is a micro-cap company in the healthcare services industry, recently transitioned to a public limited status. It has a market cap of INR 8 Cr, a P/E ratio of 8.00, and a return on equity of 10.99%.

Overview:<BR>Clinitech Laboratory Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited in 2010. The company changed its status to Public Limited and its name to Clinitech Laboratory Limited on August 25, 2023.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.05<BR>Return on Equity: 10.99%<BR>Price-to-Book: 2.10<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Clinitech Lab?

The top shareholders of Clinitech Lab include promoter Jyoti Jagdish Nayak with 29.57%, public shareholder Santosh Gopalkrishna Kudva with 6.2%, and individual investors collectively owning 36.28%. There is one foreign institutional investor holding 0.32%, and no mutual funds are currently invested in the company.

The top shareholders of Clinitech Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jyoti Jagdish Nayak, who owns 29.57% of the company. Additionally, the highest public shareholder is Santosh Gopalkrishna Kudva, holding 6.2%. Individual investors collectively own 36.28% of the shares, while there is one foreign institutional investor (FII) that holds 0.32%. There are currently no mutual funds holding shares in the company.

Who are the peers of the Clinitech Lab?

Clinitech Lab's peers include Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Sunrest Lifescie. Family Care and Sunrest Lifescie show excellent management risk, while Looks Health has the highest 1-year return at 47.37%, and Clinitech Lab's return data is unavailable.

Peers: The peers of Clinitech Lab are Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Sunrest Lifescie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care and Sunrest Lifescie, while Average management risk is found at Dr Lalchand. Lab. Below Average management risk is present at Gian Lifecare and Dhanvantri Jeev., and the rest do not qualify. Growth is rated as Good at Family Care and Sunrest Lifescie, Average at Gian Lifecare, and Below Average at Clinitech Lab and Dr Lalchand. Lab, while the rest do not qualify. Capital Structure is Excellent at Family Care, Good at Gian Lifecare, Dr Lalchand. Lab, and Dhanvantri Jeev., while Clinitech Lab and Sunrest Lifescie also have Good ratings, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 47.37%, while the lowest is Family Care at -43.73%. Clinitech Lab's 1-year return is not available for comparison. Additionally, several peers, including Gian Lifecare, Vanta Bioscience, Family Care, and Dhanvantri Jeev., have negative six-month returns.

What is the technical trend for Clinitech Lab?

As of June 5, 2025, Clinitech Lab's trend is bearish with moderate strength, supported by bearish signals from Bollinger Bands and moving averages, despite a mildly bullish weekly MACD and some divergence in the OBV.

As of 5 June 2025, the technical trend for Clinitech Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but this is overshadowed by bearish signals from the Bollinger Bands and moving averages on the daily timeframe. Additionally, both the weekly and monthly Dow Theory confirm a bearish outlook. The OBV shows a mildly bearish trend on the weekly, while the monthly is mildly bullish, suggesting some divergence. Overall, the negative performance over the past week and month further supports the bearish sentiment.

Has Clinitech Lab declared dividend?

No Dividend History Available